[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332213-105":59,"doc-detail-332213-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","retrospective-analysis-of-neoplasms-in-patients-using-angiotensin-receptor-blockers-study-of-eudravigilance-signals","Retrospective analysis of neoplasms in patients using angiotensin receptor blockers - study of EudraVigilance signals","","Retrospective safety analysis investigates reported associations between angiotensin receptor blockers (ARBs) and neoplasms following regulatory concerns about potentially carcinogenic nitrosamines and azido compounds in some ARB formulations. Spontaneous reports from the EudraVigilance Data Analysis System (EVDAS) were examined using a case/non-case disproportionality approach, calculating reporting odds ratios (RORs) and 95% confidence intervals for each ARB. Among 68,522 ARB-related safety reports, 3,396 (5%) involved neoplasms. Valsartan showed the highest neoplasm signal (ROR 1.949, 95% CI 1.857–2.046), and the association persisted versus other antihypertensive drug classes. Further studies are required to confirm and clarify mechanisms.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/retrospective-analysis-of-neoplasms-in-patients-using-angiotensin-receptor-blockers-study-of-eudravigilance-signals/332213/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/retrospective-analysis-of-neoplasms-in-patients-using-angiotensin-receptor-blockers-study-of-eudravigilance-signals/332213.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why did regulators raise concerns about angiotensin receptor blockers and neoplasms?","Question",{"text":112,"@type":113},"Regulators noted potentially carcinogenic nitrosamines and azido compounds identified in some ARB products, which are linked to an increased risk of neoplasms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the neoplasm association with ARBs evaluated in the study?",{"text":117,"@type":113},"Spontaneous safety reports from the EudraVigilance Data Analysis System were analyzed using a case/non-case disproportionality approach, calculating reporting odds ratios (RORs) with 95% confidence intervals.",{"name":119,"@type":110,"acceptedAnswer":120},"Which ARB showed the strongest signal for neoplasms?",{"text":121,"@type":113},"Valsartan had the highest neoplasm reporting signal, with ROR 1.949 (95% CI 1.857–2.046).",{"name":123,"@type":110,"acceptedAnswer":124},"Does the study conclude that ARBs cause cancer?",{"text":125,"@type":113},"The study identifies a possible safety signal and indicates the association remains significant versus other antihypertensive classes, but it emphasizes that further observational and analytical research is needed to confirm findings and explain mechanisms.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},332213,1790194922,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nRetrospective analysis of neoplasms in patients using angiotensin receptor blockers  \nArvind Kumar Sharma1,2, Shruti Rastogi2* & Ramesh K. Goyal1  \nIn recent years, regulatory agencies have raised concerns about the presence of potentially carcinogenic substances in certain formulations of Angiotensin Receptor Blockers (ARBs). Specifically, nitrosamines and azido compounds have been identified in some ARB products. Nitrosamines are known to have carcinogenic properties and are associated with an increased risk of neoplasms. Spontaneous safety reports from the EudraVigilance Data Analysis System (EVDAS) database were analyzed to investigate cases of neoplasms associated with ARBs. A disproportionality analysis was conducted, calculating the reporting odds ratio (ROR) and 95% confidence intervals (CIs) using a case/non-case approach for each ARB drug. The EVDAS database contained 68,522 safety reports related to ARBs (including Azilsartan, Candesartan, Irbesartan, Olmesartan, Losartan, Valsartan, and Telmisartan), among which 3,396 (5%) cases were associated with neoplasms. The majority of these cases were reported in Germany (11.9%), followed by France (9.7%). Approximately 70% of the reports were submitted by healthcare professionals such as physicians and nurses. Among the ARBs, valsartan had the highest ROR for neoplasm (ROR 1.949, 95% CI 1.857–2.046). This association remained significant when comparing ARBs with other classes of antihypertensive drugs, including ACE inhibitors, beta-blockers, calcium channel blockers, and diuretics. Our study identifies a possible signal of an association between ARBs, particularly valsartan, and the risk of neoplasms. However, further observational and analytical studies are necessary to confirm these findings and elucidate the underlying mechanisms.  \nKeywords Adverse drug reaction, EudraVigilance, Pharmacovigilance, Angiotensin receptor blockers, Hypertension  \nAccording to epidemiologic research, hypertension (HTN) is the most frequent disease worldwide, accounting for more than 10 crore deaths and almost 20.8 crores disability adjusted life years (DALY) worldwide1,2. In the previous 30 years, the incidence of HTN in individuals in age-group between 30 and 79 years has increased from 65 to 128 crores3. The HTN treatment guidelines recommend normal blood pressure (BP) as less than 120/80 mm Hg; elevated as 120–129/less than 80 mm Hg; HTN stage 1 as 130–139-or 80–89-mm Hg and HTN stage 2 as more than equal to 140 or more than equal to 90 mm Hg4. The growing prevalence of HTN is essentially consistent worldwide, regardless of socioeconomic position, i.e., in poorer, middle, and higher-income countries. HTN becomes more frequent with age, reaching a prevalence of more than 60% in adults over the age of 60. Successful management of HTN is the key in minimizing the disease burden and to increase the longevity in the population2.  \nThe link between BP reduction and the prevention of cardiovascular disease is widely recognized5. Thus, the need for management of HTN arises which basically involves lifestyle changes, dietary sodium restrictions, moderation of alcohol consumption, weight management, physical fitness, smoking cessation and pharmacological therapy6. The drugs recommended for the treatment of HTN are Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) inhibitors, Beta-blockers (BB), Calcium Channel Blockers (CCBs) and Diuretics7.  \nARBs are drugs that block type 1, angiotensin II receptor (AT1R)8 by displacing angiotensin II from AT1R site and increasing the stimulation of type 2, angiotensin II receptor (AT2R). AT1R is an octapeptide hormone that causes vasoconstriction, fluid and sodium retention, myocyte and smooth muscle cell hypertrophy, and is known to raise BP or cause other cardiovascular illnesses9. ARBs are known to treat HTN but are also beneficial in patient’s intolerant","cbCaijpxi8iw7SlP","https://ap.wps.com/l/cbCaijpxi8iw7SlP","pdf",1346487,"English","# Introduction\n## Background on ARBs and regulatory concerns\n# Data and Methods\n## EudraVigilance data source\n## Disproportionality analysis (ROR, 95% CIs)\n# Results\n## Geographic distribution and reporter types\n## Overall neoplasm reports and drug-specific signals\n## Comparison with other antihypertensive classes\n# Discussion and Conclusion\n## Possible biological mechanisms\n## Need for further studies","[{\"question\":\"Why did regulators raise concerns about angiotensin receptor blockers and neoplasms?\",\"answer\":\"Regulators noted potentially carcinogenic nitrosamines and azido compounds identified in some ARB products, which are linked to an increased risk of neoplasms.\"},{\"question\":\"How was the neoplasm association with ARBs evaluated in the study?\",\"answer\":\"Spontaneous safety reports from the EudraVigilance Data Analysis System were analyzed using a case/non-case disproportionality approach, calculating reporting odds ratios (RORs) with 95% confidence intervals.\"},{\"question\":\"Which ARB showed the strongest signal for neoplasms?\",\"answer\":\"Valsartan had the highest neoplasm reporting signal, with ROR 1.949 (95% CI 1.857–2.046).\"},{\"question\":\"Does the study conclude that ARBs cause cancer?\",\"answer\":\"The study identifies a possible safety signal and indicates the association remains significant versus other antihypertensive classes, but it emphasizes that further observational and analytical research is needed to confirm findings and explain mechanisms.\"}]","Retrospective analysis of neoplasms in patients using angiotensin receptor blockers - study of EudraVigilance signals | PDF",1789997352,18]